Article

Corrigendum to: Pulmonary Hypertension in Heart Failure Patients

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating

Received:

Accepted:

DOI:https://doi.org/10.15420/cfr.2020.1.1

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

In the article by Rao et al. entitled Pulmonary Hypertension in Heart Failure Patients (Cardiac Failure Review 2020;6:e05. https://doi.org/10.15420/cfr.2019.09), the following correction should be made.

The authors incorrectly stated that higher TAPSE/PASP correlates with “higher levels of natriuretic peptides, worse systemic and pulmonary haemodynamics and abnormal exercise aerobic capacity”, when it should have stated that lower TAPSE/PASP correlates with those outcomes.

The corrected sentence reads:

“Guazzi et al. showed it could be used to prognosticate in HFpEF patients, with lower TAPSE/PASP correlating with higher levels of natriuretic peptides, worse systemic and pulmonary haemodynamics and abnormal exercise aerobic capacity.”

The authors and Cardiac Failure Review apologise for this error.

Previous Volume Article Next Volume Article